organization · Reporting owner
Presidio Partners 2007 (Parallel), L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Yarrow Bioscience, Inc.
Report date July 24, 2018 · Filed July 26, 2018
Jointly reported with Presidio Partners 2007 GP, L.P., Presidio Partners 2007, L.P., Collier David J, Watson James F, Sohail Faysal A.
Section 16 reporting ended · disclosed 2018-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Presidio Partners 2007, L.P. | 1,907,568 |
Reported balance
After 2018-07-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-24 · Sale · Disposed 487,500 · Balance 1,907,568 F1: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Presidio Partners 2007 (Parallel), L.P. | 48,910 |
Reported balance
After 2018-07-24 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-07-24 · Sale · Disposed 12,500 · Balance 48,910 F2: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy David J. Collier | 152,062 |
Reported balance
Holding disclosure · report date 2018-07-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 152,062 F3: Securities directly held by David J. Collier, M.D. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein.
F2: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.
F3: Securities directly held by David J. Collier, M.D.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2018 Filed Jul 26, 2018 19:11 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | SaleCommon Stock | 12,500 | $7.65 | $95,625.00 |
DisclosureSEC source: 0001144204-18-040247 · tv499325_4.xml · nonDerivative · entry 2 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · Former 10% Owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · Former 10% Owner Presidio Partners 2007, L.P. · CIK 0001405712 · Former 10% Owner Collier David J · CIK 0001340886 · Former 10% Owner Watson James F · CIK 0001420406 · Former 10% Owner Sohail Faysal A. · CIK 0001425394 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 48,910 F2 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 19:11 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | SaleCommon Stock | 487,500 | $7.65 | $3,729,375.00 |
DisclosureSEC source: 0001144204-18-040247 · tv499325_4.xml · nonDerivative · entry 1 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · Former 10% Owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · Former 10% Owner Presidio Partners 2007, L.P. · CIK 0001405712 · Former 10% Owner Collier David J · CIK 0001340886 · Former 10% Owner Watson James F · CIK 0001420406 · Former 10% Owner Sohail Faysal A. · CIK 0001425394 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 1,907,568 F1 · ownership.nature: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. Read SEC document |
| March 02, 2018 Filed Jul 26, 2018 18:54 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | OtherCommon Stock | 152,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-040243 · tv499460_form4.xml · nonDerivative · entry 1 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By David J. Collier Disclosed balance after: 152,062 F1 · kind: Pro rata distribution from Velocity Pharmaceutical Development, LLC, of which the reporting person is a non-managing member. F2 · ownership.nature: Securities directly held by David J. Collier, M.D., a general partner of Presidio GP (as defined below), which is the sole general partner of Presidio Partners (as defined below). Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries C Preferred Stock · Derivative | 21,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 12 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries C Preferred Stock · Derivative | 343,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 11 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 0 Underlying: Common Stock · 127,269 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries B Preferred Stock · Derivative | 58,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 10 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 0 Underlying: Common Stock · 21,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries B Preferred Stock · Derivative | 2,292,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 9 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 0 Underlying: Common Stock · 849,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries A Preferred Stock · Derivative | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 8 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 0 Underlying: Common Stock · 66 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionSeries A Preferred Stock · Derivative | 6,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · derivative · entry 7 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.exercise_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F1 · derivative.expiration_date: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 3,263 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 6 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 61,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 127,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 5 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 2,395,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 21,789 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 4 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 58,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F3 · ownership.nature: Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 849,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 3 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 2,267,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F2 · ownership.nature: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 66 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 2 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007 (Parallel), L.P. Disclosed balance after: 36,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F2 · ownership.nature: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. Read SEC document |
| January 29, 2018 Filed Jan 29, 2018 16:25 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | ConversionCommon Stock | 2,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-005852 · doc4.xml · nonDerivative · entry 1 Presidio Partners 2007 GP, L.P. · CIK 0001425386 · 10% owner Presidio Partners 2007 (Parallel), L.P. · CIK 0001405972 · 10% owner Presidio Partners 2007, L.P. · CIK 0001405712 · 10% owner Collier David J · CIK 0001340886 · 10% owner Watson James F · CIK 0001420406 · 10% owner Sohail Faysal A. · CIK 0001425394 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Presidio Partners 2007, L.P. Disclosed balance after: 1,418,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock. F2 · ownership.nature: Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.